ALTEOGEN Inc. (196170.KQ)
KRW 286500.0
(-3.54%)
KRW 286500.0
(-3.54%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 440.04 Million KRW | 76.04% |
| 2022 | -6.89 Billion KRW | -104.89% |
| 2021 | -7.93 Billion KRW | -820.22% |
| 2020 | -15.02 Billion KRW | 236.92% |
| 2019 | -561.49 Million KRW | 81.39% |
| 2018 | -5.45 Billion KRW | -23.58% |
| 2017 | -6.94 Billion KRW | -13.67% |
| 2016 | -4.1 Billion KRW | -1597.35% |
| 2015 | 337.86 Million KRW | -62.06% |
| 2014 | 890.5 Million KRW | -45.62% |
| 2013 | 1.63 Billion KRW | -3.26% |
| 2012 | 1.69 Billion KRW | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -6.05 Billion KRW | -110.35% |
| 2024 Q1 | 17.91 Billion KRW | 279.2% |
| 2023 FY | - KRW | 76.04% |
| 2023 Q3 | -9.73 Billion KRW | -148.15% |
| 2023 Q4 | -7.19 Billion KRW | 26.13% |
| 2023 Q2 | 20.22 Billion KRW | 308.6% |
| 2023 Q1 | -9.69 Billion KRW | -392.1% |
| 2022 FY | - KRW | -104.89% |
| 2022 Q4 | -1.97 Billion KRW | 80.24% |
| 2022 Q3 | -9.97 Billion KRW | -14.22% |
| 2022 Q2 | -8.72 Billion KRW | -44.27% |
| 2022 Q1 | -6.05 Billion KRW | -165.78% |
| 2021 Q3 | -9.6 Billion KRW | 3.96% |
| 2021 Q4 | 9.19 Billion KRW | 195.82% |
| 2021 Q1 | -953.15 Million KRW | 87.51% |
| 2021 FY | - KRW | -820.22% |
| 2021 Q2 | -9.99 Billion KRW | -948.68% |
| 2020 Q2 | 2.96 Billion KRW | 74.44% |
| 2020 Q4 | -7.62 Billion KRW | -260.03% |
| 2020 Q3 | 4.76 Billion KRW | 60.51% |
| 2020 FY | - KRW | 236.92% |
| 2020 Q1 | 1.7 Billion KRW | -75.4% |
| 2019 Q3 | -2.79 Billion KRW | -40.06% |
| 2019 Q1 | -3.4 Billion KRW | -209.24% |
| 2019 FY | - KRW | 81.39% |
| 2019 Q4 | 6.92 Billion KRW | 347.53% |
| 2019 Q2 | -1.99 Billion KRW | 41.44% |
| 2018 FY | - KRW | -23.58% |
| 2018 Q4 | -1.1 Billion KRW | 62.96% |
| 2018 Q3 | -2.97 Billion KRW | -61.06% |
| 2018 Q2 | -1.84 Billion KRW | -56.69% |
| 2018 Q1 | -1.17 Billion KRW | 64.6% |
| 2017 Q2 | -1.96 Billion KRW | -294.37% |
| 2017 FY | - KRW | -13.67% |
| 2017 Q4 | -3.33 Billion KRW | -127.56% |
| 2017 Q1 | 1.01 Billion KRW | 166.18% |
| 2017 Q3 | -1.46 Billion KRW | 25.52% |
| 2016 Q2 | -1.3 Billion KRW | -35.52% |
| 2016 Q4 | -1.52 Billion KRW | -19.33% |
| 2016 FY | - KRW | -1597.35% |
| 2016 Q1 | -962.46 Million KRW | -246.81% |
| 2016 Q3 | -1.28 Billion KRW | 1.82% |
| 2015 Q2 | -607.36 Million KRW | -212.04% |
| 2015 Q1 | 542.12 Million KRW | 303.15% |
| 2015 FY | - KRW | -62.06% |
| 2015 Q4 | 655.57 Million KRW | 359.67% |
| 2015 Q3 | -252.45 Million KRW | 58.43% |
| 2014 Q4 | -266.86 Million KRW | -236.77% |
| 2014 FY | - KRW | -45.62% |
| 2014 Q1 | 410.3 Million KRW | 75.66% |
| 2014 Q2 | 551.93 Million KRW | 34.52% |
| 2014 Q3 | 195.12 Million KRW | -64.65% |
| 2013 FY | - KRW | -3.26% |
| 2013 Q1 | 585.16 Million KRW | 0.0% |
| 2013 Q2 | 585.16 Million KRW | 0.0% |
| 2013 Q4 | 233.57 Million KRW | 0.0% |
| 2013 Q3 | 233.57 Million KRW | -60.08% |
| 2012 FY | - KRW | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| HLB Co., Ltd. | -172.27 Billion KRW | 100.255% |
| iNtRON Biotechnology, Inc. | -6.23 Billion KRW | 107.058% |
| BINEX Co., Ltd. | 10.87 Billion KRW | 95.953% |
| Bioneer Corporation | 10.04 Billion KRW | 95.619% |
| Anterogen.Co.,Ltd. | -437.82 Million KRW | 200.506% |
| MEDIPOST Co., Ltd. | -19.39 Billion KRW | 102.269% |
| CrystalGenomics, Inc. | -42.79 Billion KRW | 101.028% |
| Helixmith Co., Ltd | -53 Billion KRW | 100.83% |
| Chabiotech Co.,Ltd. | 70.08 Billion KRW | 99.372% |
| Medy-Tox Inc. | 32.69 Billion KRW | 98.654% |
| Peptron, Inc. | -12.65 Billion KRW | 103.478% |
| Amicogen, Inc. | 13.95 Billion KRW | 96.846% |
| Genexine, Inc. | -40.87 Billion KRW | 101.076% |
| HLB Therapeutics Co.,Ltd. | 8.22 Billion KRW | 94.653% |
| LegoChem Biosciences, Inc. | -71.38 Billion KRW | 100.616% |
| PharmaResearch Co., Ltd. | 104.25 Billion KRW | 99.578% |
| SillaJen, Inc. | -17.35 Billion KRW | 102.536% |
| JETEMA, Co., Ltd. | 11 Billion KRW | 96.002% |
| OliX Pharmaceuticals,Inc | -11.13 Billion KRW | 103.952% |
| Genomictree Inc. | -6.33 Billion KRW | 106.95% |
| MedPacto, Inc. | -32.6 Billion KRW | 101.349% |
| D&D Pharmatech | -9.05 Billion KRW | 104.858% |
| EASY BIO,Inc. | 24.32 Billion KRW | 98.191% |
| GI Innovation, Inc. | -51.33 Billion KRW | 100.857% |